Clinical Trials List
2012-05-15 - 2014-04-14
Phase II
Terminated9
-
Trial Applicant
TSH BIOPHARM CORPORATION LTD.
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 黃金洲 Division of Cardiovascular Diseases
- Jaw-Wen Chen Division of Cardiovascular Diseases
- 呂信邦 Division of Cardiovascular Diseases
- Tao-Cheng Wu Division of Cardiovascular Diseases
- Wen-Chung Yu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chau-Chung Wu Division of Cardiovascular Diseases
- YEN-HUNG LIN Division of Cardiovascular Diseases
- 陳盈憲 Division of Cardiovascular Diseases
- 游治節 Division of Cardiovascular Diseases
- CHIEN-HUA HUANG Division of Cardiovascular Diseases
- Yen-Wen Wu Division of Cardiovascular Diseases
- HUNG-JU LIN Division of Cardiovascular Diseases
- 趙嘉倫 Division of Cardiovascular Diseases
- 黃惠君 Division of Cardiovascular Diseases
- WEI-TIEN CHANG Division of Cardiovascular Diseases
- MAO-HSIN LIN Division of Cardiovascular Diseases
- Hsien Li Kao Division of Cardiovascular Diseases
- Yi-Chih Wang Division of Cardiovascular Diseases
- 劉言彬 Division of Cardiovascular Diseases
- LIAN-YU LIN Division of Cardiovascular Diseases
- JYH-MING JIMMY JUANG Division of Cardiovascular Diseases
- 葉東峰 Division of Cardiovascular Diseases
- - - Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 梁凱偉 Division of Cardiovascular Diseases
- Yu-Cheng Hsieh Division of Cardiovascular Diseases
- WEI-WEN LIN Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
95 participants
-
Global
95 participants